Diabetes News and Research

Latest Diabetes News and Research

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

March of Dimes honors professor who linked fetal malnutrition to chronic adult disease

The world-renowned physician and professor who pioneered the theory linking fetal malnutrition to chronic adult disease will receive the March of Dimes Agnes Higgins Award for outstanding achievement in the field of maternal-fetal nutrition.

9 Nov 2010

Food insecurity may cause problem for diabetic patients living on fixed incomes

The economic recession impacts many aspects of our lives including an increase incidence of food insecurity. This can have serious consequences for those suffering from chronic illnesses like diabetes.

9 Nov 2010

Endeca, eHealth Ontario partner to implement chronic disease management system

Endeca Technologies, Inc., a search and business intelligence (BI) company, today announced that eHealth Ontario, an agency of the Government of Ontario, has selected Endeca and commenced work on the chronic disease management system (CDMS) and portal project previously announced in August 2010. Endeca, working with its partners, will assist with the design, build, and implementation of the system that will be used initially to better manage diabetes care throughout the province.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Arena third quarter net loss increases to $36.3 million

Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial.

9 Nov 2010

Study explains link between morbid obesity and metabolic syndrome

Scientists have found that the fat cells and tissues of morbidly obese people and animals can reach a limit in their ability to store fat appropriately. Beyond this limit several biological processes conspire to prevent further expansion of fat tissue and in the process may trigger other health problems.

9 Nov 2010

Childhood abuse increases risk of type 2 diabetes in women: Study

A new study of nearly 70,000 women found a clear association between abuse in childhood and adolescence and the risk of type 2 diabetes in adult women.

9 Nov 2010

European study indicates cardiovascular deaths can be avoided through better preventative care

Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year. Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

Duke focuses on community health in N.C.; Baltimore mental health agency's practices raise questions; Mass. clinic’s efforts to curb diabetes highlighted

The Washington Post reports on Duke University's experiment with community health centers Duke University has been focusing closer attention on the neighborhood that surrounds it by forming a partnership with Durham's Federally Qualified Health Center.

9 Nov 2010

Study finds canola-type rapeseed oil decreases fibrinogen level

According to research on fatty acids conducted at the universities of Helsinki and Tampere, the consumption of canola-type rapeseed oil decreases the level of fibrinogen detrimental to health in the body. The increased fibrinogen level, caused by an imbalance in essential fats in one's diet, decreases when saturated fatty acids are replaced with rapeseed oil.

9 Nov 2010

Pres. Obama, Indian PM Singh announce partnership to improve global food security

During a joint press conference with Indian Prime Minister Manmohan Singh on Monday, President Barack Obama announced a new partnership between U.S. and Indian agriculture sectors to help improve food security globally, Press Trust International/Livemint.com reports.

8 Nov 2010

Thirteen myths about arthritis and rheumatic disease

A diagnosis of arthritis or another rheumatic disease can cause someone to feel anxious and even a little overwhelmed. Being a knowledgeable and empowered patient can help alleviate some of those feelings, and being able to navigate through the many misconceptions about arthritis and rheumatic diseases is vitally important.

8 Nov 2010

Eli Lilly to acquire Avid Radiopharmaceuticals

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that partner company Avid Radiopharmaceuticals, Inc. has signed a definitive merger agreement to be acquired by Eli Lilly and Company.

8 Nov 2010

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.

8 Nov 2010

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Santarus, Inc. a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis.

8 Nov 2010

VIVUS closes sale of MUSE business to Meda

VIVUS, Inc. today announced that it has closed the sale of its MUSE business to Meda. Under the purchase agreement, Meda acquired the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

8 Nov 2010

Angioblast Systems receives $1.2 million in grants under QTDP program

Regenerative medicine company, Mesoblast Limited, today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

Laparoscopic surgery safe and effective for removing bowel tumours

Laparoscopic or 'keyhole' surgery is a safe, effective way of removing bowel tumours and should be offered to all patients undergoing surgery for colorectal cancer, according to researchers from the University of Leeds.

8 Nov 2010